1. In Vivo
  2. >>Deal-Making

Deals In Depth: June 2021

 
• By Maureen Riordan and Deanna Kamienski

Six $1bn+ alliances were penned in June. Topping the list was Eisai’s potential $3.1bn collaboration Bristol-Myers Squibb for the co-development and co-commercialization of Eisai’s antibody drug conjugate MORAb-202 in Japan, China, select countries in the Asia-Pacific region, the US, Canada, Europe (including the EU and UK), and Russia. The candidate is in Phase I in Japan and Phase I/II in the US for anti-folate receptor alpha-positive solid tumors.

Deals In Depth

In the top June M&A by deal value, MorphoSys AG entered into a definitive agreement to acquire public biopharma company Constellation Pharmaceuticals for $34.00 per share in cash (a 69% premium), representing a total equity value of $1.7bn. Through the acquisition, MorphoSys gets Constellation's two lead candidates pelabresib (Phase III BET inhibitor for myelofibrosis) and CPI-0209, an EZHR inhibitor in Phase II for solid and blood cancers. Financing reached $16.5bn in biopharma, $1.4bn in device, and $650m in diagnostics.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.